15 studies found for:    omalizumab, urticaria
Show Display Options
RSS Create an RSS feed from your search for:
omalizumab, urticaria
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
2 Completed Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Conditions: Chronic Urticaria;   Chronic Idiopathic Urticaria;   Chronic Spontaneous Urticaria
Interventions: Drug: Omalizumab (Xolair);   Drug: Placebo
3 Completed
Has Results
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
4 Completed
Has Results
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Placebo;   Drug: Omalizumab
5 Completed
Has Results
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab;   Drug: placebo;   Drug: H1 antihistamines;   Drug: Diphenhydramine
6 Active, not recruiting Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Biological: Omalizumab;   Biological: Placebo
7 Completed
Has Results
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo;   Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;   Drug: Diphenhydramine
8 Completed Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025;   Drug: placebo
9 Recruiting Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Condition: Chronic Urticaria
Intervention: Drug: Omalizumab
10 Recruiting Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
11 Recruiting Efficacy Study of Omalizumab in Cholinergic Urticaria
Condition: Cholinergic Urticaria
Interventions: Biological: Active;   Biological: Placebo;   Biological: Open labeled
12 Active, not recruiting Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Conditions: Chronic Spontaneous Urticaria;   Angioedema
Interventions: Biological: Omalizumab;   Drug: Placebo
13 Completed Effect of Anti-IgE in Chronic Urticaria
Condition: Urticaria
Intervention: Drug: Xolair® (Omalizumab)
14 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
15 Recruiting A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Conditions: Anaphylaxis;   Hypotension;   Bronchospasm;   Angioedema
Interventions: Drug: Epinephrine;   Procedure: Bone Marrow Apsiration;   Drug: Omalizumab (Xolair)

Indicates status has not been verified in more than two years